{"entity":{"id":"nct07465757","kind":"trial","name":"A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)","aka":[],"tldr":"A phase 2 trial of Paclitaxel / nab-paclitaxel in small-cell lung cancer, run by Puma Biotechnology, Inc., now recruiting.","summary":"A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) is a phase 2 interventional study registered as NCT07465757 by Puma Biotechnology, Inc., with 50 participants planned, started 2026-09-30 and due to reach its primary completion in 2028-03-31. Interventions recorded: Alisertib, Alisertib, Alisertib, Alisertib, Alisertib. Conditions listed: Small Cell Lung Cancer ( SCLC ). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07465757","url":"https://clinicaltrials.gov/study/NCT07465757"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["paclitaxel"],"companies":["puma-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07465757","phase":"2","setting":"A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer","sponsor":"Puma Biotechnology, Inc.","enrolled":50,"outcomes":[]},"route":"/trials/nct07465757/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"alisertib","kind":"drug","name":"Alisertib","route":"/drugs/alisertib/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"puma-biotechnology","kind":"company","name":"Puma Biotechnology","route":"/companies/puma-biotechnology/"}]}}